June 16, 2026
Winner in Fast Company’s 2026 World Changing Ideas Awards
Annual awards honor breakthrough innovations driving meaningful global impact.
Media Releases
May 26, 2026
Atmo Biosciences Receives FDA Clearance for Gastrointestinal (GI) Contractility Frequency Map
Feature addition to existing Atmo system provides clinically valuable information on gastrointestinal contractions throughout the regions of the GI tract, to better understand and manage highly prevalent dysmotility conditions.
June 27, 2025
Atmo Biosciences receives US FDA clearance for ingestible gas-sensing capsule
- US FDA 510(k) regulatory clearance enables Atmo Biosciences to market and sell its ingestible gas-sensing capsule in the USA
- Clearance is for an initial indication to aid diagnosis of gut motility disorders such as gastroparesis & slow transit constipation
- FDA clearance was supported by data from a multi-site, pivotal clinical study of the capsule which met all endpoints
April 15, 2025
Atmo Biosciences Strengthens IP Portfolio with Assignment of All Patents from RMIT University
- Atmo secures full ownership of core IP for its ingestible gas-sensing capsule
- RMIT University transfers all patents and IP in exchange for an equity stake in Atmo
- Agreement enhances Atmo’s strong IP position ahead of regulatory milestones
March 4, 2025
Atmo Biosciences announces publication of pivotal clinical study results supporting initial indication
- Pivotal clinical study data published in Clinical Gastroenterology and Hepatology. View the published study here.
- All study endpoints were achieved, with findings presented recently at major U.S. and European gastroenterology conferences.
- Data will support a U.S. FDA regulatory submission for an initial indication to evaluate whole and regional gut transit to assess common gastrointestinal motility disorders.
April 10, 2024
Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication
- Primary endpoints reached in a multi-site pivotal clinical trial.
- Data will support a regulatory submission with the FDA in Q2 CY2024 for an initial indication in gastrointestinal motility disorders.
August 10, 2023
Atmo Biosciences strengthens U.S. focus with new board appointment and establishment of San Diego office
- Multi-site clinical trial will support an initial submission for U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders such as gastroparesis and slow transit constipation.
July 7, 2023
Published trial results find Atmo Gas Capsule can detect changes in regional colonic fermentation in IBS patients
Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced results from a clinical study have found that its gas-sensing capsule can be used to provide insights into localization of colonic fermentation.
May 1, 2023
Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair
- U.S.-based Professor Quigley brings decades of experience in gastroenterological clinical practice and research as a key opinion leader at the highest levels.
October 4, 2023
Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study
- 85 patients recruited in multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.
March 30, 2023
Atmo Biosciences closes fully subscribed $8 million Series B funding round
- Capital raise led by existing shareholder Otsuka Pharmaceutical, a leading Japanese pharmaceutical company
- New capital provides funds to undertake a pivotal study to support an application for regulatory clearance in a first indication for Atmo’s unique, ingestible gas-sensing capsule to assess gastrointestinal motility
- Atmo also progressing pilot study for small intestinal bacterial overgrowth (SIBO), a common and debilitating gut disorder
July 26, 2022
Atmo Biosciences Appoints Medical Advisory Board
Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists.
May 5, 2022
Atmo Biosciences strengthens executive leadership team and Board of Directors
Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels:Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists.
October 5, 2022
Positive Atmo Capsule Clinical Trial Results Published
Atmo Biosciences, a clinical stage gut health company developing the World’s first ingestible gas-sensing capsule, is pleased to announce publication of a clinical study supporting the Atmo Gas Capsule’s ability to determine its location in the gastrointestinal tract. The study demonstrates strong agreement between data from Atmo’s Gas Capsule and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects. Based on these encouraging data, Atmo intends to conduct a clinical trial in patients with gastrointestinal motility disorders.
September 15, 2022
Atmo Biosciences and RMIT University granted US patent for Ingestible Gas Sensor Capsule
Atmo Biosciences, a clinical stage gut health company, is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule. The Atmo Gas Capsule is the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function.
